Eli Lilly India launches Tanstrive for RET-altered cancers
CDSCO-approved targeted therapy expands precision oncology options for patients with RET-driven lung, thyroid, and other advanced solid tumours
CDSCO-approved targeted therapy expands precision oncology options for patients with RET-driven lung, thyroid, and other advanced solid tumours
Subscribe To Our Newsletter & Stay Updated